<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549822</url>
  </required_header>
  <id_info>
    <org_study_id>07-109</org_study_id>
    <nct_id>NCT00549822</nct_id>
  </id_info>
  <brief_title>Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Clinical Trial of Intermittent Letrozole Therapy in Postmenopausal Women With CA 15-3 Positive (Carcinoma Antigen 15-3), Hormone Receptor Positive, Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to study the effects of using aromatase inhibitor (AI)
      therapy intermittently on participants with breast cancer. AIs are a class of drugs used to
      treat breast cancer in postmenopausal women. They work by decreasing the level of estrogen,
      which is believed to stimulate the growth of tumor tissue. Breast cancer that progresses
      despite therapy with an AI is thought to have become resistant to AI therapy. There is
      scientific evidence to suggest that resistant breast cancer cells learn to grow at the very
      low levels of estrogen present on AI therapy, and that increasing estrogen levels even
      slightly by stopping AI therapy may inhibit the breast cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This study involves treating participants with intermittent AI therapy. The AI will be
           stopped at the time they enter the study. We plan on monitoring a marker in the
           participants blood called CA 15-3 (or CA 27.29) every 4 weeks to help us make a decision
           of when to re-start treatment with letrozole (femara). This marker is known to rise when
           disease is progressing and drop when the disease is responding to treatment. We will be
           stopping and re-starting therapy based on the changes of CA 15-3 in the participants
           blood.

        -  In addition to bloodwork, the following tests and procedures will be performed on a
           monthly basis: medical history; physical examination and performance status.

        -  Every 8 weeks the following will be performed: Tumor assessment by physical exam (if
           possible); Chest x-ray or CT scan or chest; CT scans of abdomen and pelvis; and bone
           scan.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual
  </why_stopped>
  <start_date type="Actual">October 2007</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Decline in Serum CA 15-3 (Carcinoma Antigen 15-3)</measure>
    <time_frame>3 years</time_frame>
    <description>The Number of patients that have have a response of a decrease in CA 15-3 or CA 27.29 levels by at least 50% of that individual patient's baseline or peak level after re-introducing Letrozole therapy following a break in therapy as described in the intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Disease Progression With Intermittent Letrozole.</measure>
    <time_frame>3 years</time_frame>
    <description>The median time to disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HER-2/Neu Levels and Serum/Plasma Angiogenic Mediators</measure>
    <time_frame>2 years</time_frame>
    <description>Measurements for the serum HER-2/neu (human epidermal growth factor receptor 2) levels and serum/plasma angiogenic mediators</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Intermittent letrozole therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5 mg administered by mouth daily during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle based on CA 15-3 or CA 27.29 levels. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.</description>
    <arm_group_label>Intermittent letrozole therapy</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  18 years of age or older

          -  Postmenopausal

          -  Histologically or cytologically confirmed adenocarcinoma of the breast with locally
             advanced or metastatic disease this is not considered amenable to curative treatment
             with elevation of CA 15-3 documented at the time of diagnosis of metastatic disease
             and prior to initiation of letrozole or anastrozole therapy

          -  Current letrozole or anastrozole monotherapy with a documented CA 15-3 level that has
             decreased by at least 50% of the patients baseline

          -  Letrozole or anastrozole must be discontinued at the time of study enrollment

          -  Evidence of hormone sensitivity of primary or secondary tissue.

          -  Measurable or nonmeasurable (but evaluable-defined as nontarget lesions) disease
             according to modified RECIST

          -  Prior antiestrogen therapies including tamoxifen, steroidal AIs, nonsteroidal AIs, or
             fulvestrant in the adjuvant setting is allowed provided the patient is currently on
             letrozole or anastrozole monotherapy as first-line therapy for metastatic disease

          -  Life expectancy of greater than 3 months

          -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0,1, or 2

          -  Normal organ and marrow function as outlined in protocol

        Exclusion Criteria:

          -  Premenopausal

          -  Trastuzumab or biologic therapy within 2 weeks

          -  Prior or planned radiation therapy to a site of evaluable disease in the event that
             the site is the only site of evaluable disease

          -  Concomitant anticancer treatments including trastuzumab, chemotherapy, or other
             biologic agents other than letrozole or anastrozole therapy

          -  Chronic bisphosphonates for hypercalcemia or prevention of bone metastases.

          -  Treatment with non-approved or investigational agent within 2 weeks before study entry

          -  Presence of life-threatening metastatic disease, defined as extensive hepatic
             involvement, or past or present brain or leptomeningeal involvement, or symptomatic
             pulmonary lymphangitic spread

          -  Patients who are highly symptomatic from their breast cancer, or who require urgent
             palliative chemotherapy, as decided by their treating physician

          -  Previous or current systemic malignancy within the past five years, except for
             contralateral breast carcinoma, in situ carcinoma of the cervix treated by cone
             biopsy, or adequately treated basal or squamous cell carcinoma of the skin.

          -  Any severe concomitant condition believed to render subject undesirable for
             participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Goss, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2007</study_first_submitted>
  <study_first_submitted_qc>October 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2007</study_first_posted>
  <results_first_submitted>October 26, 2016</results_first_submitted>
  <results_first_submitted_qc>February 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2017</results_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Paul Goss, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>aromatase inhibitor</keyword>
  <keyword>CA 15-3</keyword>
  <keyword>Hormone receptor positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Postmenopausal patients with ER-positive (ER+) metastatic breast cancer (MBC) that were enrolled on an institutional review board (IRB) approved, phase II, multicenter clinical trial protocol (NCT00549822) evaluating intermittent AI (Aromatase Inhibitor) therapy. The study opened to accrual August 29, 2006 and closed to accrual on May 17, 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intermittent Letrozole Therapy</title>
          <description>Letrozole 2.5mg: Intermittently
Letrozole 2.5 mg administered by mouth each day during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intermittent Letrozole Therapy</title>
          <description>Letrozole 2.5mg: Intermittently
Letrozole 2.5 mg administered by mouth each day during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Decline in Serum CA 15-3 (Carcinoma Antigen 15-3)</title>
        <description>The Number of patients that have have a response of a decrease in CA 15-3 or CA 27.29 levels by at least 50% of that individual patient’s baseline or peak level after re-introducing Letrozole therapy following a break in therapy as described in the intervention.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Letrozole Therapy</title>
            <description>Letrozole 2.5mg: Intermittently
Letrozole 2.5 mg administered by mouth each day during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Decline in Serum CA 15-3 (Carcinoma Antigen 15-3)</title>
          <description>The Number of patients that have have a response of a decrease in CA 15-3 or CA 27.29 levels by at least 50% of that individual patient’s baseline or peak level after re-introducing Letrozole therapy following a break in therapy as described in the intervention.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Disease Progression With Intermittent Letrozole.</title>
        <description>The median time to disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors).</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Letrozole Therapy</title>
            <description>Letrozole 2.5mg: Intermittently
Letrozole 2.5 mg administered by mouth each day during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Disease Progression With Intermittent Letrozole.</title>
          <description>The median time to disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors).</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="28.5">Third participant did not have progressive disease during study follow-up.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum HER-2/Neu Levels and Serum/Plasma Angiogenic Mediators</title>
        <description>Measurements for the serum HER-2/neu (human epidermal growth factor receptor 2) levels and serum/plasma angiogenic mediators</description>
        <time_frame>2 years</time_frame>
        <population>Study terminated prematurely due to slow accrual. Outcome measure data not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Intermittent Letrozole Therapy</title>
            <description>Letrozole 2.5mg: Intermittently
Letrozole 2.5 mg administered by mouth each day during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum HER-2/Neu Levels and Serum/Plasma Angiogenic Mediators</title>
          <description>Measurements for the serum HER-2/neu (human epidermal growth factor receptor 2) levels and serum/plasma angiogenic mediators</description>
          <population>Study terminated prematurely due to slow accrual. Outcome measure data not available for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of treatment and twelve weeks after stopping treatment.</time_frame>
      <desc>Adverse events are recorded when reported by subjects and systematically evaluated through laboratory tests, physicals, and physician interviews every four weeks for the duration of treatment. Patients are followed for 12 weeks after removal from study or until death, whichever occurs first.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intermittent Letrozole Therapy</title>
          <description>Letrozole 2.5mg: Intermittently</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="24" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hemorrhage-other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="54" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="54" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="54" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="54" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Gr0-2 neut, sinus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory-other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back, pain</sub_title>
                <counts group_id="E1" events="53" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bone, pain</sub_title>
                <counts group_id="E1" events="54" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chest wall, pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Extremity-limb, pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Joint, pain</sub_title>
                <counts group_id="E1" events="54" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/GU-other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="54" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="54" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study closed prematurely before the planned enrollment of 20 patients due to poor patient accrual. The patient population was highly selected, were likely to have had disease with an indolent natural history.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Paul Goss</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-3118</phone>
      <email>pgoss@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

